Protecting Minors in Federal Health Plans Act
SB 1774, the “Protecting Minors in Federal Health Plans Act,” would amend the Federal Employees Health Benefits (FEHB) statute in title 5 of the U.S. Code to prohibit FEHB contracts from covering gender-affirming care or services for individuals under age 18. The bill defines gender-affirming care broadly to include medical interventions intended to treat gender dysphoria, such as hormone therapy, puberty blockers, and gender-transition surgeries.
The bill also specifies several exclusions from that definition. It carves out treatment for certain medically verifiable disorders of sexual development, care for disorders identified through genetic or biochemical testing involving atypical sex chromosome structure or hormone production/action, treatment for complications caused by prior interventions, emergency procedures needed to prevent death or major bodily impairment, and certain puberty-related treatments for precocious or delayed puberty. It also excludes male circumcision from the definition.
A limited transition provision would allow some minors already receiving covered hormone therapy as of the effective date to continue coverage only under a physician-supervised tapering schedule that ends within one year. The bill would apply to FEHB contracts entered into or renewed on or after enactment, meaning it would affect future plan years rather than immediately rewriting all existing contracts.
In practical terms, the bill would change what FEHB plans may cover for federal employees, retirees, and their dependents, and it would constrain plan administrators and insurers participating in the federal health benefits program. It would not directly regulate private insurance generally, but it would create a federal coverage restriction within one of the largest employer-sponsored health insurance programs in the country.
The available legislative record shows no votes and no committee debate transcript, so there is no documented floor or committee sentiment in the provided materials. Based on the bill’s title and text, the measure is framed as a child-protection and coverage-limitation bill, while its policy effect is to restrict access to gender-affirming care for minors in FEHB plans. The main point of contention is likely the treatment of gender-affirming care for minors versus the bill’s stated exceptions for intersex/DSD-related care, emergency care, and puberty-related treatment for non-transition purposes.
The bill would amend section 8902 of title 5, United States Code, governing the Federal Employees Health Benefits program, by adding a new prohibition on FEHB coverage for gender-affirming care or services for anyone under 18. It would directly affect federal health plan contracts, insurers participating in FEHB, and covered federal employees, annuitants, and dependents. The amendment would take effect for contracts entered into or renewed after enactment, with a narrow phase-out for certain ongoing hormone therapy.
No committee transcript or vote record is provided, so there is no direct evidence of legislative sentiment from debate or roll call. The bill’s framing suggests support from sponsors who view it as protecting minors and limiting federal coverage of gender transition-related treatments, while the subject matter itself is likely to draw opposition from advocates of gender-affirming care and LGBTQ+ rights. Overall, the available record indicates a polarized issue, but the specific chamber sentiment cannot be measured from the materials provided.
The central controversy is whether FEHB plans should be barred from covering gender-affirming care for minors, including puberty blockers, hormone therapy, and surgery. Supporters are likely to emphasize child protection, medical caution, and the bill’s exceptions for emergency care and certain non-transition-related treatments. Opponents are likely to object that the bill restricts medically recommended care for transgender youth and could interfere with physician judgment and family decision-making. Another point of contention is the bill’s detailed exclusions for disorders of sexual development and related conditions, which may be viewed either as necessary medical carve-outs or as evidence of uneven treatment of similar care.